Olympus Biotech International Ltd and BonAlive Biomaterials Ltd Announce Distribution Agreement

TURKU, Finland and LIMERICK, Ireland, January 21, 2013 /PRNewswire/ --

BonAlive Biomaterials Ltd, a manufacturer of implantable medical devices and an emerging leader in indications involving the treatment of chronically infected bone, and Olympus Biotech International Ltd, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues, today announced the signing of a multi-year exclusive distribution agreement. Under the agreement, Olympus Biotech International will have exclusive distribution rights for the BonAlive^® granules product line in Germany, France and the UK. The product line covers regenerative products for orthopaedic and trauma surgeries.

     (Logo: http://photos.prnewswire.com/prnh/20130121/589026-a )

     (Logo: http://photos.prnewswire.com/prnh/20130121/589026-b )

The agreement is an important milestone in the commercialization strategy of the BonAlive^® granules product line in the pathway of further expanding the access to hospitals in the large European markets.

"This newly established partnership enables us to work together with one of the most prominent leaders in the field of regenerative medicine in providing a complete portfolio of bone regeneration products to the community of orthopaedic and trauma surgeons" said Dr. Fredrik Ollila, CEO of BonAlive Biomaterials Ltd. "The establishment of a complete product offering will generate value and bring new opportunities in treatment of chronically infected bone".

"The cooperation and agreement with BonAlive Biomaterials Ltd completes our bone regeneration portfolio now also in the treatment of fractures and non-unions in patients with chronic infections. During our thorough global assessment of different technologies and options we were impressed by the clinical evidence and clinical data available for BonAlive®. We are very much convinced to have decided for a partnership with the company having the right approach to improve patient outcome" said Florian Kemmerich, President of Olympus Biotech International.

For more information about BonAlive Biomaterials Ltd, please visit http://www.bonalive.com

For more information about Olympus Biotech, visit http://www.olympusbiotech.com

About BonAlive Biomaterials Ltd

BonAlive Biomaterials Ltd is an emerging leader in the field of implantable medical devices for bone regeneration. The focus is to provide world-leading biomaterial solutions for the treatment of chronically infected bone. BonAlive^® products are available in Europe, Middle East, Asia-Pacific, Africa, Brazil and the USA through a professional distributor network. The clinical use of BonAlive^® is supported by a twenty year research history including several randomized prospective trials in the field of spine, benign bone tumor and trauma surgery. More than fifty peer reviewed articles have been published about BonAlive^®.

About Olympus Biotech International Limited

Olympus Biotech was established in December, 2010 as a wholly owned company of Olympus Corporation. The vision of Olympus Biotech is to improve the patient Quality of Life by developing and distributing Regenerative Medicine that stimulates the intrinsic healing capacity in the living body. Olympus Biotech provides minimally-invasive regenerative therapies for bone and soft tissue including growth factors, scaffolds and cell harvesting technologies as well as tools for access, placement and delivery.

For questions or additional information, please contact:

Olympus Biotech International Limited
Dirk Dembski
Vice President Marketing and Business Development
Olympus Biotech International  
Mobile +49-172-2492700
dirk.dembski@olympusbiotech.com

BonAlive Biomaterials Ltd:
Fredrik Ollila, PhD
Chief Executive Officer
BonAlive Biomaterials Ltd
Mobile +358(0)400-931-209
Fax +358(0)421-917-744-00
fredrik.ollila@bonalive.com

SOURCE BonAlive Biomaterials Ltd